vs
ARTIVION, INC.（AORT）与GLAUKOS Corp（GKOS）财务数据对比。点击上方公司名可切换其他公司
GLAUKOS Corp的季度营收约是ARTIVION, INC.的1.2倍（$143.1M vs $116.0M）。ARTIVION, INC.净利率更高（2.1% vs -93.4%，领先95.5%）。GLAUKOS Corp同比增速更快（35.7% vs 19.2%）。GLAUKOS Corp自由现金流更多（$3.9M vs $-7.9M）。过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs 9.1%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
AORT vs GKOS — 直观对比
营收规模更大
GKOS
是对方的1.2倍
$116.0M
营收增速更快
GKOS
高出16.5%
19.2%
净利率更高
AORT
高出95.5%
-93.4%
自由现金流更多
GKOS
多$11.9M
$-7.9M
两年增速更快
GKOS
近两年复合增速
9.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $143.1M |
| 净利润 | $2.4M | $-133.7M |
| 毛利率 | 63.1% | -1.1% |
| 营业利润率 | 9.2% | -97.7% |
| 净利率 | 2.1% | -93.4% |
| 营收同比 | 19.2% | 35.7% |
| 净利润同比 | 114.7% | -298.0% |
| 每股收益（稀释后） | $0.06 | $-2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTGKOS
| Q4 25 | $116.0M | $143.1M | ||
| Q3 25 | $113.4M | $133.5M | ||
| Q2 25 | $113.0M | $124.1M | ||
| Q1 25 | $99.0M | $106.7M | ||
| Q4 24 | $97.3M | $105.5M | ||
| Q3 24 | $95.8M | $96.7M | ||
| Q2 24 | $98.0M | $95.7M | ||
| Q1 24 | $97.4M | $85.6M |
净利润AORTGKOS
| Q4 25 | $2.4M | $-133.7M | ||
| Q3 25 | $6.5M | $-16.2M | ||
| Q2 25 | $1.3M | $-19.7M | ||
| Q1 25 | $-505.0K | $-18.1M | ||
| Q4 24 | $-16.5M | $-33.6M | ||
| Q3 24 | $-2.3M | $-21.4M | ||
| Q2 24 | $-2.1M | $-50.5M | ||
| Q1 24 | $7.5M | $-40.8M |
毛利率AORTGKOS
| Q4 25 | 63.1% | -1.1% | ||
| Q3 25 | 65.6% | 78.4% | ||
| Q2 25 | 64.7% | 78.3% | ||
| Q1 25 | 64.2% | 77.2% | ||
| Q4 24 | 63.2% | 72.9% | ||
| Q3 24 | 63.7% | 76.6% | ||
| Q2 24 | 64.6% | 76.4% | ||
| Q1 24 | 64.6% | 76.3% |
营业利润率AORTGKOS
| Q4 25 | 9.2% | -97.7% | ||
| Q3 25 | 11.1% | -12.3% | ||
| Q2 25 | 7.4% | -18.3% | ||
| Q1 25 | 2.2% | -19.4% | ||
| Q4 24 | 2.7% | -27.2% | ||
| Q3 24 | 4.6% | -25.5% | ||
| Q2 24 | 6.6% | -31.3% | ||
| Q1 24 | 26.0% | -45.6% |
净利率AORTGKOS
| Q4 25 | 2.1% | -93.4% | ||
| Q3 25 | 5.7% | -12.2% | ||
| Q2 25 | 1.2% | -15.8% | ||
| Q1 25 | -0.5% | -17.0% | ||
| Q4 24 | -16.9% | -31.8% | ||
| Q3 24 | -2.4% | -22.1% | ||
| Q2 24 | -2.2% | -52.8% | ||
| Q1 24 | 7.7% | -47.7% |
每股收益（稀释后）AORTGKOS
| Q4 25 | $0.06 | $-2.34 | ||
| Q3 25 | $0.13 | $-0.28 | ||
| Q2 25 | $0.03 | $-0.34 | ||
| Q1 25 | $-0.01 | $-0.32 | ||
| Q4 24 | $-0.40 | $-0.56 | ||
| Q3 24 | $-0.05 | $-0.39 | ||
| Q2 24 | $-0.05 | $-1.00 | ||
| Q1 24 | $0.18 | $-0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $90.8M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $656.2M |
| 总资产 | $884.8M | $893.5M |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTGKOS
| Q4 25 | $64.9M | $90.8M | ||
| Q3 25 | $73.4M | $98.2M | ||
| Q2 25 | $53.5M | $100.8M | ||
| Q1 25 | $37.7M | $114.3M | ||
| Q4 24 | $53.5M | $169.6M | ||
| Q3 24 | $56.2M | $100.1M | ||
| Q2 24 | $55.0M | $68.1M | ||
| Q1 24 | $51.1M | $42.5M |
总债务AORTGKOS
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTGKOS
| Q4 25 | $448.2M | $656.2M | ||
| Q3 25 | $438.7M | $769.5M | ||
| Q2 25 | $419.9M | $765.1M | ||
| Q1 25 | $294.3M | $764.0M | ||
| Q4 24 | $276.2M | $766.9M | ||
| Q3 24 | $304.7M | $668.5M | ||
| Q2 24 | $295.1M | $665.2M | ||
| Q1 24 | $295.0M | $450.7M |
总资产AORTGKOS
| Q4 25 | $884.8M | $893.5M | ||
| Q3 25 | $857.7M | $999.4M | ||
| Q2 25 | $838.4M | $987.0M | ||
| Q1 25 | $791.2M | $966.2M | ||
| Q4 24 | $789.1M | $974.8M | ||
| Q3 24 | $803.1M | $926.5M | ||
| Q2 24 | $789.5M | $919.7M | ||
| Q1 24 | $784.0M | $933.3M |
负债/权益比AORTGKOS
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $6.8M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $3.9M |
| 自由现金流率自由现金流/营收 | -6.9% | 2.7% |
| 资本支出强度资本支出/营收 | 23.7% | 2.0% |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | $-22.5M |
8季度趋势，按日历期对齐
经营现金流AORTGKOS
| Q4 25 | $19.6M | $6.8M | ||
| Q3 25 | $22.3M | $-10.1M | ||
| Q2 25 | $15.0M | $7.0M | ||
| Q1 25 | $-17.0M | $-18.5M | ||
| Q4 24 | $10.1M | $507.0K | ||
| Q3 24 | $11.5M | $-9.6M | ||
| Q2 24 | $6.1M | $-18.4M | ||
| Q1 24 | $-5.5M | $-33.9M |
自由现金流AORTGKOS
| Q4 25 | $-7.9M | $3.9M | ||
| Q3 25 | $17.7M | $-11.7M | ||
| Q2 25 | $11.7M | $5.8M | ||
| Q1 25 | $-20.6M | $-20.5M | ||
| Q4 24 | $8.7M | $-1.2M | ||
| Q3 24 | $7.8M | $-11.0M | ||
| Q2 24 | $3.6M | $-20.5M | ||
| Q1 24 | $-9.1M | $-34.8M |
自由现金流率AORTGKOS
| Q4 25 | -6.9% | 2.7% | ||
| Q3 25 | 15.6% | -8.8% | ||
| Q2 25 | 10.4% | 4.7% | ||
| Q1 25 | -20.8% | -19.2% | ||
| Q4 24 | 9.0% | -1.2% | ||
| Q3 24 | 8.2% | -11.4% | ||
| Q2 24 | 3.7% | -21.4% | ||
| Q1 24 | -9.3% | -40.7% |
资本支出强度AORTGKOS
| Q4 25 | 23.7% | 2.0% | ||
| Q3 25 | 4.1% | 1.2% | ||
| Q2 25 | 2.9% | 0.9% | ||
| Q1 25 | 3.7% | 1.8% | ||
| Q4 24 | 1.5% | 1.6% | ||
| Q3 24 | 3.8% | 1.5% | ||
| Q2 24 | 2.6% | 2.2% | ||
| Q1 24 | 3.7% | 1.1% |
现金转化率AORTGKOS
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | 11.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
